Dr. Jack Puymirat M.D., Ph.D., is a neurologist, clinician-scientist at the CHU Research Centre of Quebec, and professor in the Department of Medicine at Laval University. His work focuses on the study of neuromuscular diseases, headaches, as well as the development of a platform for the production of induced pluripotent human stem cells. Recently, his work on stem cell production was featured on Radio-Canada’s Découverte program. He has received several nominations, including the 2006 Researcher of the Year Award from Muscular Dystrophy Canada and the 2011 Hans Steinert Award from international myotonic dystrophy (Steinert’s disease) consortium.
Research on neuromuscular diseases
Steinert myotonic dystrophy is a muscular dystrophy that is 20 times more prevalent in the Saguenay-Lac-Saint-Jean region than anywhere else in the world. In 2000, it was established that the disease was due to the accumulation of mutated RNAs in the cell nucleus. Dr. Puymirat’s research has focused on the development of gene therapy, based on the destruction of toxic RNAs by antisense oligonucleotides. In 2016, his work led to the first Phase 1 clinical trial in the United States. In parallel with his research, Dr. Puymirat and his team have a clinical research program focusing on: 1) The establishment of a provincial registry for this disease to facilitate research and patient participation in clinical trials. 2) The development and validation of protocols for the quantification of muscle strength, the study of muscle imaging and the search for biomarkers of the disease for future clinical trials. 3) The development of genetic tests for various neuromuscular diseases, tests which are now used clinically and offered to the population of Quebec.
The induced pluripotent stem cells production platform (iPSC)
Thanks to the financial support of Brain Canada, Dr. Puymirat and his team have developed a platform for the production of induced pluripotent human stem cells. These cells can be derived from skin, blood, urine and immortalized lymphoblastic cell lines. These cells can differentiate into various cell types, particularly neurons, muscle cells and heart cells. They are used to model neurodegenerative, neuromuscular and psychiatric diseases, screen drugs, and develop cell therapies.
Pharmacogenomics in migraine
This research aims to identify blood molecular markers that are predictive of the response to different drugs used in the treatment of migraine. As a first step, Dr. Puymirat and his team are developing a migraine patient registry, which is essential for genomics studies. This registry contains information on the response to different drugs and will be extended to the CHUM as well as the Montreal Neurological Institute.
R-211, LOEX/ CMDGT
Québec, Québec,, Québec
Canada G1J 1Z4
Latest news
Data not available
- Cossette, LouiseEmployeeHôpital de l'Enfant-Jésus+1 418-525-4444, extension 64344louise.cossette@crchudequebec.ulaval.ca
1401 18 ième rue
H501
Québec, Québec
Canada G1J 1Z4 - De Serres-Bérard, ThiéryDoctoral studentHôpital de l'Enfant-Jésus+1 418-525-4444, extension 61673thiery.de-serres-berard.1@ulaval.cathiery.de_serres-berard@crchudequebec.ulaval.ca
1401 18 ième Rue
R-112
Québec, Québec
Canada G1J 1Z4 - Simard, AlexandraEmployeeHôpital de l'Enfant-Jésus+1 418-649-0252, extension 63559Alexandra.Simard@crchudequebec.ulaval.ca
1401, 18e Rue
Recherche neuromusculaire
P-0145
Québec, Québec
Canada G1J 1Z4 - Tanguay, MichèleEmployeeHôpital de l'Enfant-Jésusmichele.tanguay@crchudequebec.ulaval.ca
1401 18e Rue
H-501
Québec, QC
Canada G1J 1Z4
Correction to: Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
Journal ArticleOrphanet J Rare Dis, 14 (1), 2019.
The DM-scope registry: a rare disease innovative framework bridging the gap between research and medical care
Journal ArticleOrphanet J Rare Dis, 14 (1), 2019.
Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice
Journal ArticleJ Clin Invest, 129 (11), 2019.
Differentiation of lymphoblastoid-derived iPSCs into functional cardiomyocytes, neurons and myoblasts
Journal ArticleBiochem Biophys Res Commun, 516 (1), 2019.
Consensus-based care recommendations for adults with myotonic dystrophy type 1
Journal ArticleNeurol Clin Pract, 8 (6), 2018.
Ankle Strength Impairments in Myotonic Dystrophy Type 1: A Five-Year Follow-up
Journal ArticleJ Neuromuscul Dis, 5 (3), 2018.
Lymphoblastoids cell lines - Derived iPSC line from a 26-year-old myotonic dystrophy type 1 patient carrying (CTG) expansion in the DMPK gene: CHUQi001-A
Journal ArticleStem Cell Res, 26 , 2018.
rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences
Journal ArticleNat Commun, 9 (1), 2018.
Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
Journal ArticleOrphanet J Rare Dis, 13 (1), 2018.
Implication of SPARC in the modulation of the extracellular matrix and mitochondrial function in muscle cells
Journal ArticlePLoS One, 13 (2), 2018.
Active projects
- Recherche clinique visant à identifier les facteurs prédicateurs de la réponse au traitement de la migraine par l'Aimovig , from 2020-04-30 to 2025-03-31
Recently finished projects
- Human iPSC-derived neurons as a model of congenital myotonic dystrophy type 1, from 2021-05-01 to 2023-04-30
- Phase I/II clinical trial of myoblast transplantation to Duchenne Muscular Dystrophy patients., from 2013-10-01 to 2022-03-31